Citations

Clear

6274 citation(s) found for "To, Andrew".

NCOG-03. IMPACT OF THE RATE OF RADIOGRAPHIC RESPONSE (RR) OF BRAIN METASTASES (BM) TO WHOLE BRAIN RADIATION THERAPY (WBRT) ON NEUROCOGNITIVE FUNCTION (NCF) ON NRG-CC001
Devisetty, Kiran , Pugh, Stephanie, Brown, Paul D. , Gondi, Vinai , Solanki, Abhishek A. , Kalapparambath, Tomy, Harmon, Grant, Saripalli, Anjali L. , Chou, Brian, Venkatesulu, Bhanu Prasad , Boike, Thomas , Bovi, Joseph , McGee, Mackenzie, Baschnagel, Andrew, Usuki, Kenneth Y., Kachnic, Lisa A. , Wefel, Jeffrey S. , Kundapur, Vijayananda , Roberge, David , Kruser, Tim J. , Baschnagel, Andrew, Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii197-vii197

10.1093/neuonc/noac209.756 Get It

Abstract BACKGROUND The assessment of BM response to WBRT and its impact on NCF in clinical trials has been limited by lack of standardized imaging protocols. NRG-CC001 is a randomized clinical trial requiring pre-specified MRI protocols at baseline and 6-months, providing a uniform dataset to investigate if RR correlates with NCF changes. METHODS NRG-CC001 randomized patients with BM to hippocampal avoidance WBRT (HA-WBRT) or WBRT. NCF was analyzed using 6-month standardized change scores and deterioration, defined using the reliable change index. Chi-square and t-tests were used for pretreatment characteristic comparisons. Inter-rater reliability between central and institutional assessment of RR was assessed with weighted kappa, κ. Linear regression was used to test trends in NCF change scores across types of response and multivariable logistic regression was used to test the association of RR to NCF deterioration. RESULTS 149 and 135 patients were evaluable for RR and NCF assessment, respectively. Pretreatment characteristics were well-balanced, except for post-high school education (70.6% HA-WBRT vs. 52.5% WBRT, p=0.023). Inter-rater reliability between central and institutional assessment of RR was fair (κ=0.36). There was no difference between arms in RR (p=0.41) with overall rates of 14.1% CR, 42.2% PR, 17% SD, and 26.7% PD. Patients with CR had improved 6-month NCF change as measured by HVLT-R Total Recall (p=0.0005), HVLT-R Delayed Recall (p=0.0003), HVLT-R Delayed Recognition (p=0.011), TMT-B (p=0.033), COWA (p=0.016), and Clinical Trial Battery Composite score (p=0.0011). Multivariable analysis demonstrated less deterioration in HVLT-R Delayed Recall for CR (p=0.019) and PR (p=0.0086) vs. SD/PD and HVLT-R Recognition for PR (p=0.031) vs. SD/PD. CONCLUSIONS HA-WBRT and WBRT result in similar RR at 6-months. CR or PR is associated with better NCF preservation. This suggests investigation into treatment escalation for patients with SD/PD may provide further NCF benefit along with HA-WBRT and memantine.Grant support from NCI-UG1CA189867 and U24CA180803.
PATH-34. SOLITARY FIBROUS TUMOR: NATURAL HISTORY AND PROGNOSIS IN ACCORDANCE WITH THE WHO 2021 CLASSIFICATION OF CNS TUMORS
Jenkins, Sarah M. , Fritchie, Karen , Moskalev, Evgeny A. , Caron, Alissa, Link, Michael , Brown, Paul D. , Guajardo, Andrew, Wu, Ashely, Louis, David N. , Kaplan, Alexander , Ferrarese, Fabio, Raleigh, David R. , Vega, Jose Velazquez, Alverez, Maria Martinez-Lage, Haller, Florian , Eschbacher, Kathryn L. , Brat, Daniel J. , Santagata, Sandro , Brastianos, Priscilla K. , Alexander, Brian M. , Rossi, Sabrina , Nguyen, Minh, Gross, John , Vega, José E. Velázquez , Rodríguez, Fausto J. , Perry, Arie , Giannini, Caterina

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii157-vii158

10.1093/neuonc/noac209.607 Get It

Abstract Meningeal solitary fibrous tumor (SFT) is a rare tumor with high propensity to recur and metastasize, even late in the course of disease. The WHO 2021 classification of CNS tumors divides SFT in 3 grades, based on mitotic index and necrosis. We re-examined our cohort of 126 patients (57 F, 69 M; mean age 53.0 years) with SFT, confirmed by STAT6 nuclear positivity and/or NAB2::STAT6 fusion, with extended follow-up (median 7.6 years; range 4 days-26.6 years). Tumors included 76 grade 1, 36 grade 2 and 14 grade 3 according to 2021 WHO criteria, evaluated at primary resection (n=90), recurrence (n=35), or metastasis (n=1). Fifty-six patients had one or more post-surgical events, the earliest event being local recurrence (n=41) or metastasis (n=15). Forty patients died (29 of disease; 9 of other causes; 2 unknown). Overall survival (OS), and progression-free survival (PFS, recurrence and/or metastasis) from time of primary resection (n=90) were not significantly associated with grade; however, risk of metastasis differed significantly (5-year estimates: 4.1%, 15.3%, and 37.8% for grades 1, 2, and 3 SFT, respectively; p=0.005). NAB2::STAT6 fusion status was known in 101 cases (51 = ex5-7-ex16-17, 26 = ex4_ex2-3; 12 = ex2-3_exANY/other and 12 =no fusion). Disease specific 5-year survival in primary tumors with molecular data (n = 75) was 80.0% in patients whose tumors harbored ex5-7_ex16-17 compared to 93.3% in all others combined (p=0.014). Targeted TERT promoter mutation testing was performed in 98 patients, revealing patients with tumors lacking TERT promoter mutation (n = 88) were younger at time of surgery than those harboring a mutation (n=10; p = 0.022), and none with a mutation harboring concurrent ex5-7_ex16-17 fusion (p = 0.0009). In summary, WHO 2021 grade is associated with risk of metastasis. Patients whose tumors harbor ex5-7_ex16-17 fusion have a higher risk of dying from the disease.
NIMG-42. DURABLE OVERALL RESPONSE RATE (ORR) TARGETS FOR RECURRENT GLIOBLASTOMA (RGBM) CLINICAL TRIALS BASED ON THE HISTORIC ASSOCIATION BETWEEN ORR AND MEDIAN OVERALL SURVIVAL (MOS)
Wen, Patrick Y. , Chang, Susan M. , Vogelbaum, Michael A. , Li, Gang, Lassman, Andrew B. , Gilbert, Mark, Ellingson, Benjamin M. , Wen, Patrick Yung , Bent, Martin J. van den , Li, Shanpeng , Kim, Jiyoon , Youssef, Gilbert , Wick, Wolfgang , Groot, John de , Weller, Michael , Galanis, Evanthia , Cloughesy, Timothy F.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii172-vii173

10.1093/neuonc/noac209.660 Get It

Abstract Durable overall response rate (ORR) remains a meaningful endpoint in recurrent GBM; however, the target ORR for single arm recurrent GBM trials has not been based on historic information or tied to patient outcomes. The current study reviewed past trials in recurrent GBM in order to judiciously define target ORRs for use in recurrent GBM trials. After reviewing 69 treatment arms comprising 4,971 patients, ORR was 6.1%[95% CI 4.23; 8.76%] for cytotoxic chemotherapies (ORR=7.59% for CCNU, 7.57% for TMZ, 0.64% for CPT-11, and 5.32% for other agents), 3.37% for biologic agents, 7.97% for immunotherapies (select trials), and 26.8% for anti-angiogenic agents. ORRs were significantly correlated with median overall survival (mOS) across chemotherapy (R2=0.4078, P< 0.0001), biologics (R2=0.4003, P=0.0003), and immunotherapy trials (R2=0.8994, P< 0.0001), but not anti-angiogenic agents (R2=0, P=0.8937). Pooling data from chemotherapy, biologics, and immunotherapy trials, a meta-analysis indicated a strong correlation between ORR and mOS (R2=0.3164, P< 0.0001; mOS[weeks]=0.6xORR+28.9), suggesting an ORR >20% results in an mOS of > 40.9 weeks, which is double the survival estimate of a treatment with ORR=0% and ≥ 2 months longer than treatments with ORR=5%. Assuming an ineffective therapy (control) has ORR=5%, a trial of 32 patients with a target ORR=20% leads to the 95% confidence interval higher than the control group. We conclude that single arm phase II studies in recurrent GBM with ≥ 32 patients should have a target ORR ≥ 20%. This was associated with a median OS of approximately 1 year. Importantly, durability of response should also be considered and was not assessed in the current meta-analysis.
Monitoring and diagnosis of intermittent arrhythmias: evidence-based guidance and role of novel monitoring strategies
Carrington, M , Providência, Rui , Epstein, Andrew E. , Gallina, Sabina , Fedorowski, Artur , Sutton, Richard , Carrington, Mafalda , Fedorowski, Artur , Sutton, Richard , Providencia, Rui , Chahal, C. Anwar A. , Ricci, Fabrizio , Khanji, Mohammed Y

Mayo Clinic

European Heart Journal Open | November 12, 2022 | Volume: 2 | Issue: 6 | Pages: No page available

10.1093/ehjopen/oeac072 | PMID 36440351 Get It

Abstract Technological advances have made diagnosis of heart rhythm disturbances much easier, with a wide variety of options, including single-lead portable devices, smartphones/watches to sophisticated implantable cardiac monitors, allowing accurate data to be collected over different time periods depending on symptoms frequency. This review provides an overview of the novel and existing heart rhythm testing options, including a description of the supporting evidence for their use. A description of each of the tests is provided, along with discussion of their advantages and limitations. This is intended to help clinicians towards choosing the most appropriate test, thus improving diagnostic yield management of patients with suspected arrhythmias.
Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702
Lee, Seohyuk , Ma, Chao , Shi, Qian , Kumar, Pankaj , Couture, Félix , Kuebler, Philip , Krishnamurthi, Smitha , Lewis, DeQuincy Andrew, Goldberg, Richard M. , Blanke, Charles D. , Shields, Anthony F. , Meyerhardt, Jeffrey A. , Kuebler, J. Philip , Goldberg, Richard M , Venook, Alan P , O'Reilly, Eileen M , Shields, Anthony F , Meyerhardt, Jeffrey A , Shi, Qian , Kumar, Pankaj , Tan, Benjamin, Venook, Alan P. , O’Reilly, Eileen M.

Mayo Clinic

Journal of Clinical Oncology | November 11, 2022 | Volume: 41 | Issue: 5 | Pages: 1079-1091

10.1200/jco.22.01637 | PMID 36367997 Get It

PURPOSE We sought to evaluate the independent and interactive associations of planned treatment duration, celecoxib use, physical activity, body mass index (BMI), diabetes mellitus, and vitamin B6 with oxaliplatin-induced peripheral neuropathy (OIPN) among patients with stage III colon cancer enrolled in a clinical trial. METHODS We conducted a prospective, observational study of 2,450 patients with stage III colon cancer enrolled in the CALGB/SWOG 80702 trial, randomly assigned to 6 versus 12 cycles of adjuvant fluorouracil, leucovorin, and oxaliplatin chemotherapy with or without 3 years of celecoxib. OIPN was reported using the Common Terminology Criteria for Adverse Events (CTCAE) during and following completion of chemotherapy and the FACT/GOG-NTX-13 15-17 months after random assignment. Multivariate analyses were adjusted for baseline sociodemographic and clinical factors. RESULTS Patients assigned to 12 treatment cycles, relative to 6, were significantly more likely to experience higher-grade CTCAE- and FACT/GOG-NTX-13-reported neuropathy and longer times to resolution, while neither celecoxib nor vitamin B6 intake attenuated OIPN. Exercising ≥ 9 MET-hours per week after treatment relative to < 9 was associated with improvements in FACT/GOG-NTX-13-reported OIPN (adjusted difference in means, 1.47; 95% CI, 0.49 to 2.45; P = .003). Compared with patients with baseline BMIs < 25, those with BMIs ≥ 25 were at significantly greater risk of developing higher-grade CTCAE-reported OIPN during (adjusted odds ratio, 1.18; 95% CI, 1.00 to 1.40; P = .05) and following completion (adjusted odds ratio, 1.23; 95% CI, 1.01 to 1.50; P = .04) of oxaliplatin treatment. Patients with diabetes were significantly more likely to experience worse FACT/GOG-NTX-13-reported neuropathy relative to those without (adjusted difference in means, –2.0; 95% CI, –3.3 to –0.73; P = .002). There were no significant interactions between oxaliplatin treatment duration and any of these potentially modifiable exposures. CONCLUSION Lower physical activity, higher BMI, diabetes, and longer planned treatment duration, but not celecoxib use or vitamin B6 intake, may be associated with significantly increased OIPN severity.
Magnetic resonance radiomic feature performance in pulmonary nodule classification and impact of segmentation variability on radiomics
Koo, Chi Wan , Kline, Timothy L. , Yoon, Joo Hee , Vercnocke, Andrew J. , Johnson, Mathew P, Suman, Garima , Lu, Aiming , Larson, Nicholas B. , Larson, Nicholas B

Mayo Clinic

The British Journal of Radiology | November 11, 2022 | Volume: 95 | Issue: 1140 | Pages: No page available

10.1259/bjr.20220230 | PMID 36367095 Get It

Objective: Investigate the performance of multiparametric MRI radiomic features, alone or combined with current standard-of-care methods, for pulmonary nodule classification. Assess the impact of segmentation variability on feature reproducibility and reliability. Methods: Radiomic features were extracted from 74 pulmonary nodules of 68 patients who underwent nodule resection or biopsy after MRI exam. The MRI features were compared with histopathology and conventional quantitative imaging values (maximum standardized uptake value [SUVmax] and mean Hounsfield unit [HU]) to determine whether MRI radiomic features can differentiate types of nodules and associate with SUVmax and HU using Wilcoxon rank sum test and linear regression. Diagnostic performance of features and four machine learning (ML) models were evaluated with area under the receiver operating characteristic curve (AUC) and 95% confidence intervals (CIs). Concordance correlation coefficient (CCC) assessed the segmentation variation impact on feature reproducibility and reliability. Results: Elevn diffusion-weighted features distinguished malignant from benign nodules (adjusted p < 0.05, AUC: 0.73–0.81). No features differentiated cancer types. Sixty-seven multiparametric features associated with mean CT HU and 14 correlated with SUVmax. All significant MRI features outperformed traditional imaging parameters (SUVmax, mean HU, apparent diffusion coefficient [ADC], T1, T2, dynamic contrast-enhanced imaging values) in distinguishing malignant from benign nodules with some achieving statistical significance (p < 0.05). Adding ADC and smoking history improved feature performance. Machine learning models demonstrated strong performance in nodule classification, with extreme gradient boosting (XGBoost) having the highest discrimination (AUC = 0.83, CI=[0.727, 0.932]). We found good to excellent inter- and intrareader feature reproducibility and reliability (CCC≥0.80). Conclusion: Eleven MRI radiomic features differentiated malignant from benign lung nodules, outperforming traditional quantitative methods. MRI radiomic ML models demonstrated good nodule classification performances with XGBoost superior to three others. There was good to excellent inter- and intrareader feature reproducibility and reliability. Advances in knowledge: Our study identified MRI radiomic features that successfully differentiated malignant from benign lung nodules and demonstrated high performance of our MR radiomic feature-based ML models for nodule classification. These new findings could help further establish thoracic MRI as a non-invasive and radiation-free alternative to standard practice for pulmonary nodule assessment.
Endoscopic ultrasound-guided gastroenterostomy for the management of gastric outlet obstruction: A large comparative study with long-term follow-up
Jaruvongvanich, Veeravich , Mahmoud, Tala , Law, Ryan , Levy, Michael J. , Marya, Neil B. , Abboud, Donna Maria , Ghazi, Rabih , Matar, Reem, Rapaka, Babusai , Buttar, Navtej , Truty, Mark J. , Aerts, Maridi , Messaoudi, Nouredin , Kunda, Rastislav , Abboud, Donna M, Abboud, Donna M , Dayyeh, Barham K. Abu , Chandrasekhara, Vinay , Storm, Andrew C. , Levy, Michael J. , Vargas, Eric J. , Marya, Neil B.

Mayo Clinic

Endoscopy International Open | November 10, 2022 | Volume: 11 | Issue: 01 | Pages: E60-E66

10.1055/a-1976-2279 | PMID 36644538 Get It

Abstract Background and study aims Gastric outlet obstruction (GOO) is traditionally managed with surgical gastroenterostomy (surgical-GE) and enteral stenting (ES). Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is now a third option. Large studies assessing their relative risks and benefits with adequate follow-up are lacking. We conducted a comparative analysis of patients who underwent EUS-GE, ES, or surgical-GE for GOO. Patients and methods In this retrospective comparative cohort study, consecutive patients presenting with GOO who underwent EUS-GE, ES, or surgical-GE at two academic institutions were reviewed and independently cross-edited to ensure accurate reporting. The primary outcome was need for reintervention. Secondary outcomes were technical and clinical success, length of hospital stay (LOS), and adverse events (AEs). Results A total of 436 patients (232 EUS-GE, 131 ES, 73 surgical-GE) were included. The median duration of follow-up of the entire cohort was 185.5 days (interquartile range 55.25–454.25 days). The rate of reintervention in the EUS-GE group was lower than in the ES and surgical-GE groups (0.9 %, 12.2 %, and 13.7 %, P < 0.0001). Technical success was achieved in 98.3 %, 99.2 %, and 100 % (P = 0.58), and clinical success was achieved in 98.3 %, 91.6 %, and 90.4 % (P < 0.0001) in the EUS-GE, ES, and surgical-GE groups, respectively. The EUS-GE group had a shorter LOS (2 days vs. 3 days vs. 5 days, P < 0.0001) and a lower AE rate than the ES and surgical-GE groups (8.6 % vs. 38.9 % vs. 27.4 %, P < 0.0001). Conclusion This large cohort study demonstrates the safety and palliation durability of EUS-GE as an alternative strategy for GOO palliation in select patients.
Financial Impact of a Culturally Sensitive Hispanic Kidney Transplant Program on Increasing Living Donation
Mathur, Amit K. , Ruiz, Richard , Wang, Andrew , Caicedo, Juan Carlos , Gordon, Elisa J.

Mayo Clinic

Transplantation | November 8, 2022 | Volume: 107 | Issue: 4 | Pages: 970-980

10.1097/tp.0000000000004382 | PMID 36346212 Get It

Background. In the United States, Hispanic/Latinx patients receive disproportionately fewer living donor kidney transplants (LDKTs) than non-Hispanic White patients. Northwestern Medicine’s culturally targeted Hispanic Kidney Transplant Program (HKTP) was found to increase LDKTs in Hispanic patients at 1 of 2 transplant programs with greater implementation fidelity. Methods. We conducted a budget impact analysis to evaluate HKTP’s impact on program financial profiles from changes in volume of LDKTs and deceased donor kidney transplants (DDKTs) in 2017 to 2019. We estimated HKTP programmatic costs, and kidney transplant (KT) program costs and revenues. We forecasted transplant volumes, HKTP programmatic costs, and KT program costs and revenues for 2022–2024. Results. At both programs, HKTP programmatic costs had <1% impact on total KT program costs, and HKTP programmatic costs comprised <1% of total KT program revenues in 2017–2019. In particular, the total volume of Hispanic KTs and HKTP LDKTs increased at both sites. Annual KT program revenues of HKTP LDKTs and DDKTs increased by 226.9% at site A and by 1042.9% at site B when comparing 2019–2017. Forecasted HKTP LDKT volume showed an increase of 36.4% (site A) and 33.3% (site B) with a subsequent increase in KT program revenues of 42.3% (site A) and 44.3% (site B) among HKTP LDKTs and DDKTs. Conclusions. HKTP programmatic costs and KT evaluation costs are potentially recoverable by reimbursement of organ acquisition costs and offset by increases in total KT program revenues of LDKTs; transplant programs may find implementation of the HKTP financially manageable.
1244 Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events
Kozono, David , Watson, Mark , Wen, Yujia , Keller, Frank G. , Naidoo, Jarushka , Mulhern, Barb, Hoffman, Laura, Naidoo, Jarushka , Kozono, David E , Zemla, Tyler , Dib, Elie G. , Watson, Mark, Kirkwood, John M. , Lyman, Gary H , Le‐Rademacher, Jennifer , Nixon, Andrew B. , Sharon, Elad

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A1290-A1291

10.1136/jitc-2022-sitc2022.1244 Get It